The use of this test in clinical practice would allow for the avoidance of side effects and the implementation of more effective treatment. "We've found a way to practice precision medicine with standard chemotherapy," says Geoff Macintyre, a researcher at the Spanish National Cancer Research Centre (CNIO). The research has been published in the journal Nature Genetics. The test will now be validated in a hospital setting, thanks to a new project funded by the Spanish Ministry for Digital Transformation and Public Service.

Penn-led researchers have engineered a powerful cancer-fighting compound from Aspergillus flavus, a toxic fungus linked to ancient tomb deaths. The modified molecules showed potent effects against leukemia cells, rivaling FDA-approved drugs and opening new paths in the search for fungal-derived medicines.

In a paper published in MedComm – Future Medicine, a Chinese research team presents ImmunoCheckDB, a comprehensive web platform integrating meta-analysis and multiomic data to discover cancer immunotherapy biomarkers. The platform curates 173 studies on immune checkpoint inhibitor (ICI) therapies, covering survival outcomes for 93,234 individuals across 18 cancer types and 30 ICI regimens, enabling pan-cancer exploration of molecular markers for ICI efficacy.

- Development of "dynamic nanomedicines" for efficient delivery of nucleic acid medicines to sentinel lymph nodes.

- Delivering nucleic acid medicines to sentinel lymph nodes, which serve as a checkpoint for cancer metastasis, activates the immune system, helping to suppress cancer metastasis and recurrence.

- Enhancing cancer immunotherapy to make it effective against immunotherapy-resistant tumors.

- Precise size adjustment of nanomedicines (approximately 10 nm) enables delivery to sentinel lymph nodes.

- Precision nanomedicine design via advanced computational modelling.

- Aim to start clinical trials within five years.

- This announcement is part of a research project conducted by Professor Kanjiro Miyata of the Graduate School of Engineering, The University of Tokyo (Visiting Research Scientist at iCONM), in collaboration with iCONM researchers.

A new cancer treatment that delivers radiation directly to tumors by targeting two key markers simultaneously has been shown to be safe and effective in human trials. Acting like a “smart missile,” the dual-targeting radiopharmaceutical is designed to attach to two vulnerable sites on cancer cells, enabling more precise and potent therapy. Early results show that nearly 90 percent of patients experienced either tumor shrinkage or disease stabilization. These findings were presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting.